M. S. Zinkovich
M. S. Zinkovich has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anna S. Goncharova
National Medical Research Centre for Oncology Rostov-on-Don, Russian Federation
4 shared publications - Marina Aleksandrovna Gusareva
National Medical Research Centre for Oncology
4 shared publications - Anastasia V. Galina
National Medical Research Centre for Oncology Rostov-on-Don, Russian Federation
3 shared publications - E. V. Zaikina
National Medical Research Centre for Oncology
3 shared publications - M.V. Mindar
National Medical Research Centre for Oncology
3 shared publications - Lyudmila Ya. Rozenko
National Medical Research Centre for Oncology
2 shared publications
Latest Publications
- Open Access
- 13 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 6-13
Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
Purpose of the study. Assessment of clinical safety and effectiveness of radium‑223 in patients with bone metastases from castration-resistant prostate cancer.Patients and methods. The study involved materials on 15 patients with bone metastases from castration-resistant prostate cancer aged 58–81 years, with the mean age of 67.2 ± 6.5 years, who were examined and received full treatment with 6 intravenous injections of radium‑223 chloride [223Ra] at the National Medical Research Centre for Oncology. Most patients (73.3 %) showed ECOG 1 performance status. Pain syndrome before the treatment was registered in 12 (80 %) patients.Results. Evaluation of the tolerability of radium chloride did not show hematological reactions such as anemia and thrombocytopenia. One patient had grade II intestinal toxicity after the 3rd injection managed with medication. Assessment of indirect signs of the treatment effectiveness demonstrated that 6 people showed an increase in PSA during treatment, while alkaline phosphatase levels were within normal range indicating no bone destruction. 8 of 12 patients with pain syndrome showed its relief during the therapy. The following results were obtained during a follow-up examination after 3 months in 15 patients who received the full treatment course: stabilization in 8 patients; improvement in 4 patients with decreased metabolic activity and lower numbers of metastatic foci; progression with the appearance of new metastatic foci in the bones in 3 patients.Conclusion. Radium chloride showed good results in the treatment of patients with bone metastases from castration-resistant prostate cancer. Low toxicity and improvement in the quality of life by pain relief make this treatment technique promising.
- 13 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 6-13
Open AccessIntravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
Purpose of the study. Assessment of clinical safety and effectiveness of radium‑223 in patients with bone metastases from castration-resistant prostate cancer.Patients and methods. The study involved materials on 15 patients with bone metastases from castration-resistant prostate cancer aged 58–81 years, with the mean age of 67.2 ± 6.5 years, who were examined and received full treatment with 6 intravenous injections of radium‑223 chloride [223Ra] at the National Medical Research Centre for Oncology. Most patients (73.3 %) showed ECOG 1 performance status. Pain syndrome before the treatment was registered in 12 (80 %) patients.Results. Evaluation of the tolerability of radium chloride did not show hematological reactions such as anemia and thrombocytopenia. One patient had grade II intestinal toxicity after the 3rd injection managed with medication. Assessment of indirect signs of the treatment effectiveness demonstrated that 6 people showed an increase in PSA during treatment, while alkaline phosphatase levels were within normal range indicating no bone destruction. 8 of 12 patients with pain syndrome showed its relief during the therapy. The following results were obtained during a follow-up examination after 3 months in 15 patients who received the full treatment course: stabilization in 8 patients; improvement in 4 patients with decreased metabolic activity and lower numbers of metastatic foci; progression with the appearance of new metastatic foci in the bones in 3 patients.Conclusion. Radium chloride showed good results in the treatment of patients with bone metastases from castration-resistant prostate cancer. Low toxicity and improvement in the quality of life by pain relief make this treatment technique promising.
- Open Access
- 7 August 2023
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 4 (3) , 36-43
Gastric cancer modeling in immunodeficient mice with orthotopic xenotransplantation
Purpose of the study. Creation of a transplantable orthotopic PDX model of gastric cancer in Balb/c Nude immunodeficient mice using implantation and injection.Materials and methods. Two methods, that are injection and implantation, were used to create an orthotopic PDX model of human gastric cancer. The first method involved injections of a suspension of a mechanically disaggregated patient's tumor after filtration into the gastric wall of Balb/c Nude mice. For the second method, small fragments (3 × 3 × 3 mm) of patients' tumors were implanted in the gastric wall of mice along the greater curvature with a dissection of the serous muscular layer.Results. Control laparotomy in Balb/c Nude immunodeficient mice showed a successful engraftment of the tumor material at the 1st and 3rd procedures when using the implantation method for the creation of a PDX model of gastric cancer. The injection method was ineffective, and no models were created. The histological type of the obtained PDX models was compared to the type of the donor tumor by histological examination (hematoxylin and eosin staining). The tumor grade remained stable and did not change during xenograft passage, which showed that the obtained model was identical to the histotype of the donor tumor.Conclusion. The presented implantation method for the model creation results in effective tumor engraftment. The developed model can be used to test the effectiveness of anticancer or antimetastatic drugs, for studying the functions of biomarkers, or in assessing the microenvironment of a gastric cancer.
- 7 August 2023
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 4 (3) , 36-43
Open AccessGastric cancer modeling in immunodeficient mice with orthotopic xenotransplantation
Purpose of the study. Creation of a transplantable orthotopic PDX model of gastric cancer in Balb/c Nude immunodeficient mice using implantation and injection.Materials and methods. Two methods, that are injection and implantation, were used to create an orthotopic PDX model of human gastric cancer. The first method involved injections of a suspension of a mechanically disaggregated patient's tumor after filtration into the gastric wall of Balb/c Nude mice. For the second method, small fragments (3 × 3 × 3 mm) of patients' tumors were implanted in the gastric wall of mice along the greater curvature with a dissection of the serous muscular layer.Results. Control laparotomy in Balb/c Nude immunodeficient mice showed a successful engraftment of the tumor material at the 1st and 3rd procedures when using the implantation method for the creation of a PDX model of gastric cancer. The injection method was ineffective, and no models were created. The histological type of the obtained PDX models was compared to the type of the donor tumor by histological examination (hematoxylin and eosin staining). The tumor grade remained stable and did not change during xenograft passage, which showed that the obtained model was identical to the histotype of the donor tumor.Conclusion. The presented implantation method for the model creation results in effective tumor engraftment. The developed model can be used to test the effectiveness of anticancer or antimetastatic drugs, for studying the functions of biomarkers, or in assessing the microenvironment of a gastric cancer.
- Open Access
- 1 February 2023
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 4 (1) , 52-64
Modern approaches to glioblastoma therapy
Glioblastoma (GBM) is the most malignant and the most common primary tumor of the central nervous system. During the last several years GBM has been classified and managed according to the World Health Organization (WHO) criteria which subdivide it into primary and secondary GBM. As it is suggested, GBM originates from glial cells and has a diffuse growth pattern, but its etiology and pathophysiology are poorly investigated up to date. Its rapid progression and anatomical location in the brain often limits the effectiveness of therapeutic interventions. Despite all scientific and technological advances, GBM remains an incurable disease with a median survival of approximately 18 months. Standard treatment options involving maximal safe resection of the tumor followed with radiotherapy and chemotherapy do not provide satisfactory Results.Better understanding of the molecular pathology of GBM and its associated signaling pathways has opened up possibilities for new treatments for newly diagnosed and relapsing tumors. A multitargeted therapeutic approach using compounds capable of inhibiting more than one specific molecular target is a promising alternative to conventional therapies.Currently, specialists study such innovative treatment options as small molecule inhibitors aimed at signaling pathway disruptions, immunotherapy, including checkpoint inhibitors, oncolytic vaccines, CAR T-cell therapy, and drug delivery systems. In terms of an innovative approach, the elaboration of targeted drug delivery systems is of particular interest, since this strategy looks the most promising due to its ability to increase the bioavailability and effectiveness of both standard and newly tested agents. This review discusses results of preclinical and clinical studies of innovative therapeutic approaches, their advantages and disadvantages. An interdisciplinary approach is expected to be able to combine the results of cutting-edge research in this area and to provide novel promising therapeutic strategies for patients with GBM.
- 1 February 2023
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 4 (1) , 52-64
Open AccessModern approaches to glioblastoma therapy
Glioblastoma (GBM) is the most malignant and the most common primary tumor of the central nervous system. During the last several years GBM has been classified and managed according to the World Health Organization (WHO) criteria which subdivide it into primary and secondary GBM. As it is suggested, GBM originates from glial cells and has a diffuse growth pattern, but its etiology and pathophysiology are poorly investigated up to date. Its rapid progression and anatomical location in the brain often limits the effectiveness of therapeutic interventions. Despite all scientific and technological advances, GBM remains an incurable disease with a median survival of approximately 18 months. Standard treatment options involving maximal safe resection of the tumor followed with radiotherapy and chemotherapy do not provide satisfactory Results.Better understanding of the molecular pathology of GBM and its associated signaling pathways has opened up possibilities for new treatments for newly diagnosed and relapsing tumors. A multitargeted therapeutic approach using compounds capable of inhibiting more than one specific molecular target is a promising alternative to conventional therapies.Currently, specialists study such innovative treatment options as small molecule inhibitors aimed at signaling pathway disruptions, immunotherapy, including checkpoint inhibitors, oncolytic vaccines, CAR T-cell therapy, and drug delivery systems. In terms of an innovative approach, the elaboration of targeted drug delivery systems is of particular interest, since this strategy looks the most promising due to its ability to increase the bioavailability and effectiveness of both standard and newly tested agents. This review discusses results of preclinical and clinical studies of innovative therapeutic approaches, their advantages and disadvantages. An interdisciplinary approach is expected to be able to combine the results of cutting-edge research in this area and to provide novel promising therapeutic strategies for patients with GBM.
- Open Access
- 1 February 2023
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 4 (1) , 6-13
Immunohistochemical assessment of possible anticancer effect mechanisms of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)- 5,6,7-trichloro-1,3-tropolone in PDX models of lung cancer
Purpose of the study. Evaluation of the expression of immunohistochemical tumor markers Ki-67, b-catenin, Bcl-2, P53, connexin 32 and connexin 43 when using 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone in mice with xenographs of squamous cell lung cancer.Materials and methods. Subcutaneous PDX models of human squamous cell lung cancer were created in immunodeficient BALB/c Nude mice. A fragment of the patient’s tumor (3 × 3 × 3 mm) was implanted subcutaneously in the right thigh of a previously anesthetized mouse. 200 μl of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone was administered orally using a probe in 12 doses once every 3 days. All animals were divided into groups depending on the tropolone doses: experimental groups 2–5 with doses of 0.0055, 0.055, 0.55 and 2.75 mg/g, respectively. The control group received 1 % starch gel which was tropolone carrier. The animals were euthanized 36 days after the start of the substance administration, and the tumor tissue was isolated and prepared for the IHC study according to the standard protocol. IHC reactions were performed using antibodies for Ki-67, b-catenin, Bcl-2, P53, connexin 32 and connexin 43.Results. Higher tropolone doses were associated with decreased expression of Ki-67, b-catenin, and the Bcl-2 protein, but increased expression of the P53 protein. The dosage of tropolone and expression of connexin 43 were directly proportional.Conclusion. Immunohistochemical analysis of expression of proteins in PDX models of human squamous cell lung cancer when using 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone showed the changes indicating its antitumor efficacy and suggesting a possible mechanism of action based on the activation of apoptosis.
- 1 February 2023
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 4 (1) , 6-13
Open AccessImmunohistochemical assessment of possible anticancer effect mechanisms of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)- 5,6,7-trichloro-1,3-tropolone in PDX models of lung cancer
Purpose of the study. Evaluation of the expression of immunohistochemical tumor markers Ki-67, b-catenin, Bcl-2, P53, connexin 32 and connexin 43 when using 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone in mice with xenographs of squamous cell lung cancer.Materials and methods. Subcutaneous PDX models of human squamous cell lung cancer were created in immunodeficient BALB/c Nude mice. A fragment of the patient’s tumor (3 × 3 × 3 mm) was implanted subcutaneously in the right thigh of a previously anesthetized mouse. 200 μl of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone was administered orally using a probe in 12 doses once every 3 days. All animals were divided into groups depending on the tropolone doses: experimental groups 2–5 with doses of 0.0055, 0.055, 0.55 and 2.75 mg/g, respectively. The control group received 1 % starch gel which was tropolone carrier. The animals were euthanized 36 days after the start of the substance administration, and the tumor tissue was isolated and prepared for the IHC study according to the standard protocol. IHC reactions were performed using antibodies for Ki-67, b-catenin, Bcl-2, P53, connexin 32 and connexin 43.Results. Higher tropolone doses were associated with decreased expression of Ki-67, b-catenin, and the Bcl-2 protein, but increased expression of the P53 protein. The dosage of tropolone and expression of connexin 43 were directly proportional.Conclusion. Immunohistochemical analysis of expression of proteins in PDX models of human squamous cell lung cancer when using 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone showed the changes indicating its antitumor efficacy and suggesting a possible mechanism of action based on the activation of apoptosis.
- Open Access
- 23 March 2018
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 9 (1) , 32-41
The influence of xenon-therapy on tolerance of adjuvant radiotherapy in patients with single brain metastasis
Влияние ксенонотерапии на переносимость адъювантной лучевой терапии у пациентов с одиночным метастатическим поражением головного мозга
- 23 March 2018
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 9 (1) , 32-41
Open AccessThe influence of xenon-therapy on tolerance of adjuvant radiotherapy in patients with single brain metastasis
Влияние ксенонотерапии на переносимость адъювантной лучевой терапии у пациентов с одиночным метастатическим поражением головного мозга